<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NAFARELIN ACETATE</span><br/>(na-fa're-lin)<br/><span class="topboxtradename">Synarel<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">gonadotropin-releasing hormone analog</span><br/><b>Prototype: </b>Leuprolide<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL nasal solution</p>
<h1><a name="action">Actions</a></h1>
<p>Potent agonist analog of gonadotropin-releasing hormone (GnRH). Inhibits pituitary gonadotropin secretion of LH and FSH.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decrease in serum estradiol or testosterone concentrations results in the quiescence of tissues and functions that depend
         on LH and FSH.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Endometriosis and precocious puberty.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Uterine leiomyomas, benign prostatic hypertrophy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to GnRH or GnRH agonist analog; undiagnosed abnormal vaginal bleeding; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Polycystic ovarian disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Endometriosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Inhalation</span> 2 inhalations/d (200 mcg/inhalation), one in  each nostril, begin between days 2 and 4 of menstrual cycle; in patients with persistent regular menstruation after 2 mo of
               therapy, may increase to 800 mcg/d as 2 inhalations (one in each nostril) b.i.d.; continue therapy for 6 mo, retreatment is
               not advised because of lack of safety data<br/><br/><span class="indicationtitle">Precocious Puberty</span><br/><span class="rdage">Child:</span> <span class="rdroute">Inhalation</span> 8001200 mcg/d divided q8h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Inhalation</span><br/><ul>
<li>Withhold any topical nasal decongestant, if being used, until at least 30 min after nafarelin administration.</li>
<li>Store at 15°30° C (59°86° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Bloating, abdominal cramps,</span> weight gain, nausea. <span class="typehead">Endocrine:</span> <span class="speceff-common">Hot flashes, anovulation, amenorrhea, vaginal dryness,</span> galactorrhea. <span class="typehead">Metabolic:</span> Decreased bone mineral content (reversible). <span class="typehead">CNS:</span> Transient headache, inertia, mild depression, moodiness, fatigue. <span class="typehead">Respiratory:</span> Nasal irritation. <span class="typehead">Urogenital:</span> <span class="speceff-common">Impotence, decreased libido,</span> dyspareunia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increased <span class="alt">alkaline phosphatase;</span> marked increase in <span class="alt">estradiol</span> in first 2 wk, then decrease to below baseline; decreased <span class="alt">FSH</span> and <span class="alt">LH</span> levels; decreased <span class="alt">testosterone</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 21% absorbed from nasal mucosa. <span class="typehead">Onset:</span> 4 wk. <span class="typehead">Peak:</span> 12 wk. <span class="typehead">Duration:</span> 3050 d after discontinuing drug. <span class="typehead">Distribution:</span> 7884% bound to plasma proteins; crosses placenta. <span class="typehead">Metabolism:</span> Hydrolyzed in kidney. <span class="typehead">Elimination:</span> 4455% excreted in urine over 7 d, 1944% in feces. <span class="typehead">Half-Life:</span> 2.7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Make appropriate inquiries about breakthrough bleeding, which may indicate that patient has missed successive drug doses.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Read the information pamphlet provided with nafarelin.</li>
<li>Inform physician if breakthrough bleeding occurs or menstruation persists.</li>
<li>Use or add barrier contraceptive during treatment.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>